Adverse Effects of Red Blood Cell Transfusions: A Unifying Hypothesis (Aim 3)
INOBA
1 other identifier
interventional
43
1 country
1
Brief Summary
Transfusion of red blood cells is often used in critically ill patients with low red blood cell counts to prevent disease progression and death. Recent studies suggest that the use of "aged" versus "fresh" red blood cells are associated with worse clinical outcomes. There is evidence that red blood cells work with the cells lining our blood vessels to produce a variety of substances that normally cause arteries to relax and increase blood supply. Two of these substances are called nitric oxide (NO) and endothelium-derived hyperpolarizing factor (EDHF). The investigators are trying to determine the nature of these substances in human beings when they are transfused "aged" versus "fresh" red blood cells. The purpose of the study is to test the effects of transfusing "aged" versus "fresh" red blood cells in volunteers with traditional cardiovascular risk factors (high blood pressure, diabetes, high cholesterol, and tobacco use) on 1) the degree of relaxation in the arteries and subsequent changes in blood flow, 2) blood levels of oxidant molecules, 3) inflammation, and 4) stem cells. A similar study with healthy volunteers are further described in NCT00838331.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_2 cardiovascular-diseases
Started Apr 2009
Typical duration for phase_2 cardiovascular-diseases
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2013
CompletedFirst Submitted
Initial submission to the registry
October 29, 2014
CompletedFirst Posted
Study publicly available on registry
October 31, 2014
CompletedResults Posted
Study results publicly available
December 4, 2014
CompletedApril 11, 2016
April 1, 2016
3.6 years
October 29, 2014
November 4, 2014
April 7, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Brachial Artery Flow-mediated Dilation (FMD) After Fresh Red Blood Cells (RBCs) Transfusions vs. Storage-aged Red Blood Cells (saRBCs) Transfusions at Baseline
Ultrasonography of the brachial artery performed at the bedside using a high-resolution 10-megahertz (MHz) ultrasound transducer before and after suprasystolic inflation of a blood pressure cuff for 5 minutes in the ipsilateral upper arm. Brachial artery FMD was calculated as (hyperemic diameter - baseline diameter)/baseline diameter × 100.
Baseline
Brachial Artery Flow-mediated Dilation (FMD) After Fresh Red Blood Cells (RBCs) Transfusions vs. Storage-aged Red Blood Cells (saRBCs) Transfusions at 24 Hours After Transfusion
Ultrasonography of the brachial artery performed at the bedside using a high-resolution 10-megahertz (MHz) ultrasound transducer before and after suprasystolic inflation of a blood pressure cuff for 5 minutes in the ipsilateral upper arm. Brachial artery FMD was calculated as (hyperemic diameter -24 hour diameter)/24 hour diameter × 100.
24 hours after transfusion
Study Arms (2)
Storage-aged red blood cells (saRBCs)
ACTIVE COMPARATORSubjects with cardiovascular disease (CVD) received a transfusion with older stored red blood cells (RBCs) units. The units had been stored for greater than 21 days.
Fresh red blood cells (RBCs)
ACTIVE COMPARATORSubjects with cardiovascular disease (CVD) received a transfusion with fresh red blood cells (RBCs) units. The units had been stored for less than 14 days.
Interventions
Packed RBCs units stored for greater than 21 days, with a mean storage duration of 29.6 ± 4.9 days (mean ± SD)
Packed RBCs units stored for less than 14 days, with a mean storage duration of 9.6 ± 3.9 days (mean ± SD)
Eligibility Criteria
You may qualify if:
- Inpatient or outpatient at Emory University Hospital who's physicians have ordered a transfusion of packed red blood cells (pRBCs) of 1 or more units
- Cardiovascular risk factors (hypercholesterolemia, diabetes, hypertension, and tobacco smoking) or known cardiovascular disease) will be carefully documented for each subject
- Cardiac risk factors are defined as follows:
- Hypercholesterolemia: Defined as serum low density lipoprotein cholesterol \> 140 mg/dL if not currently on lipid-lowering therapy or \> 100 mg/dL if on lipid-lowering therapy
- Diabetes: Defined as having fasting blood glucose sample of \> 126 mg/dL or a hemoglobin A1c of \> 7% or being treated with diabetes medications such as oral hypoglycemic agents, insulin sensitizing agents, or subcutaneous insulin
- Smoking: active tobacco use, 20 cigarettes per day for the past year
- Hypertension: Blood pressure of \> 140/90 or currently on anti-hypertensive medications
- Cardiovascular disease: known coronary artery disease by angiogram or documented myocardial infarction
You may not qualify if:
- Pregnancy
- Previous transfusion within one week.
- Inability to give informed consent
- On oral or IV nitrate therapy
- On vasopressor agents
- Active illicit drug use
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Emory Universitylead
Study Sites (1)
Emory University
Atlanta, Georgia, 30322, United States
MeSH Terms
Conditions
Limitations and Caveats
Only patients receiving routine transfusions were included in the study, thus excluding critically ill/actively bleeding patients requiring emergent transfusions.
Results Point of Contact
- Title
- Dr. John D. Roback
- Organization
- Emory University
Study Officials
- PRINCIPAL INVESTIGATOR
John Roback, MD, PhD
Emory University
Publication Agreements
- PI is Sponsor Employee
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
October 29, 2014
First Posted
October 31, 2014
Study Start
April 1, 2009
Primary Completion
November 1, 2012
Study Completion
October 1, 2013
Last Updated
April 11, 2016
Results First Posted
December 4, 2014
Record last verified: 2016-04